Search Results
Post Hoc Analysis of Sustained MRD Negativity (GRIFFIN Trial) in TE NDMM Patients
Impact of sustained MRD negativity and CR after ide-cel in patients with multiple myeloma
FORTE: MRD negativity as key prognostic factor in NDMM
The FORTE trial: the value of sustained MRD negativity
The immune microenvironment predicts sustained MRD-negativity after D-KRd treatment for myeloma
DARA+RVd in Pts w/Transplant Eligible Newly Diagnosed Multiple Myeloma after 24 Months Maintenance
Sustained MRD negativity in multiple myeloma
GRIFFIN: follow-up after DARA + RVd for multiple myeloma
MRD negativity using deep sequencing is a major prognostic factor in myeloma
Management of Multiple Myeloma: Updates - S. M. Rubinstein - 20240828
An update on GMMG HD7: Isa-RVd vs RVd & lenalidomide-isatuximab vs lenalidomide maintenance in NDMM
Dr. Voorhees on Updated Depth of Response in GRIFFIN Trial in Multiple Myeloma
